点击图片查看原图
(HCV NS5B)重组丙型肝炎病毒NS5B
SCF (human):Fc (mouse) (rec.)
PAR2 Agonist peptide
7-表紫杉醇 7-Epi-Pac
头孢妥仑匹酯JP,△-3
长春布宁 Vinburnine 
Y-27632 dihydrochlor
老刺木胺 Voacamine(V
法筚枝苷 Fabiatrin C
硫酸长春碱 CAS：143-
醋酸多瑞肽 Doreptide| 货号： | C13884 |
| CAS号： | 83461-56-7 |
| 供应商： | 凯立德生物 |
| 数量： | 5/3/2/51 |
| 英文名： | Mifamurtide |
| 保质期： | 2年 |
| 保存条件： | 2-8℃ |
| 规格： | 20mg/100mg/1g/5g |
产品别名：Muramyl tripeptide phosphatidylethanolamine; N-(N-Acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamide
CAS： 83461-56-7
交货期：现货
分子式：C59H109N6O19P
分子量：1237.50
生物活性：
Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.
Target: Others
Mifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].
相关文献：
[1]. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53.
[2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.
温馨提示：不可用于临床治疗。
